| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| IRONMAN: International Registry for Men with Advanced Prostate Cancer | CTRIAL-IE 17-30 | Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC) |
The purpose of this study is to create an international, population-based, |
DSSG Group: Genitourinary
Includes the following types of cancers:
PEACE III
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| PEACE III | CTRIAL-IE 16-21 | asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone |
The purpose of this study is to find out whether the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) shows better activity against Xtandi® alone (enzalutamide) in metastatic prostate cancer and if the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) is safe. |
NRG GU005
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| NRG GU005 | CTRIAL-IE 18-02 | Localised intermediate risk prostate cancer |
To determine if stereotactic body radiation therapy (SBRT) is superior to hypofractionated intensity modulated radiation therapy (IMRT) in the treatment of localised intermediate risk prostate cancer. |